Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 28;48(9):2883–2893. doi: 10.1007/s00259-021-05353-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Images in 46-year-old man. a Baseline FDG PET maximum intensity projection (upper row) and axial PET/CT fusion image (lower row) show intense FDG uptake in a bulky mass within the left pelvis. b Interim FDG PET maximum intensity projection (upper row) and axial PET/CT fusion image (lower row) show decreased activity, but the lesion remained positive (arrow) due to an area with visually higher than liver FDG uptake. c Interim FLT PET image (upper row) and axial PET/CT fusion image (lower row) show photopenic tracer uptake in this lesion, which was considered negative for disease. d End-of-treatment FDG PET maximum intensity projection shows (upper row) and axial PET/CT fusion image (lower row) substantial reduction in FDG activity which is visually same with mediastinal FDG uptake. This patient remains without evidence of recurrence for 3 years from initiation of treatment